ketotifen has been researched along with Acquired Immunodeficiency Syndrome in 4 studies
Ketotifen: A cycloheptathiophene blocker of histamine H1 receptors and release of inflammatory mediators. It has been proposed for the treatment of asthma, rhinitis, skin allergies, and anaphylaxis.
ketotifen : An organic heterotricyclic compound that is 4,9-dihydro-10H-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one which is substituted at position 4 by a 1-methylpiperidin-4-ylidene group. A blocker of histamine H1 receptors with a stabilising action on mast cells, it is used (usually as its hydrogen fumarate salt) for the treatment of asthma, where it may take several weeks to exert its full effect.
Acquired Immunodeficiency Syndrome: An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effect of the testosterone derivative oxymetholone alone or in combination with the H1-receptor antagonist ketotifen, which has recently been shown to block tumour necrosis factor alpha (TNF alpha), on weight gain and performance status in human immunodeficiency virus (HIV) patients with chronic cachexia was evaluated in a 30-week prospective pilot study." | 9.08 | Oxymetholone promotes weight gain in patients with advanced human immunodeficiency virus (HIV-1) infection. ( Baumann, M; Brockmeyer, NH; Goos, M; Hengge, UR; Maleba, R, 1996) |
| "The effect of the testosterone derivative oxymetholone alone or in combination with the H1-receptor antagonist ketotifen, which has recently been shown to block tumour necrosis factor alpha (TNF alpha), on weight gain and performance status in human immunodeficiency virus (HIV) patients with chronic cachexia was evaluated in a 30-week prospective pilot study." | 5.08 | Oxymetholone promotes weight gain in patients with advanced human immunodeficiency virus (HIV-1) infection. ( Baumann, M; Brockmeyer, NH; Goos, M; Hengge, UR; Maleba, R, 1996) |
| "Thalidomide may cause birth defects, and larger doses can cause neuropathy or other adverse effects." | 1.29 | Wasting syndrome--affordable treatments. ( James, JS, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hengge, UR | 1 |
| Baumann, M | 1 |
| Maleba, R | 1 |
| Brockmeyer, NH | 1 |
| Goos, M | 1 |
| Smart, T | 1 |
| Grunfeld, C | 1 |
| James, JS | 1 |
1 trial available for ketotifen and Acquired Immunodeficiency Syndrome
| Article | Year |
|---|---|
Oxymetholone promotes weight gain in patients with advanced human immunodeficiency virus (HIV-1) infection.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anabolic Agents; Body Mass Index; Cachexia; Drug Therapy, | 1996 |
3 other studies available for ketotifen and Acquired Immunodeficiency Syndrome
| Article | Year |
|---|---|
Other therapies for wasting.
Topics: Acquired Immunodeficiency Syndrome; Anabolic Agents; Cannabidiol; Dronabinol; Female; Humans; Ketoti | 1995 |
State of the art in wasting: an interview with Carl Grunfeld, PhD. Interview by Jeff Getty.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Animals; Cachexia; Endocr | 1995 |
Wasting syndrome--affordable treatments.
Topics: Acquired Immunodeficiency Syndrome; Cachexia; Costs and Cost Analysis; Dronabinol; Exercise Therapy; | 1995 |